-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written byWang Cong
EditorWang Multifish
TypesettingShui Chengwen
Multiple Sclerosis (MS) is a neurodegenerative disease, Because the immune system mistakenly attacks and destroys the myelin sheath, involving the optic nerve, spinal cord, brainstem, periventricular white matter and other parts, resulting in clinical symptoms such as abnormal vision, limb movement disorder and ataxia, patients will gradually lose sensation and function
in the limbs and other parts of the body.
Although a variety of treatments for multiple sclerosis have been developed, there is no cure, and these therapies mainly target relapsing-remitting multiple sclerosis (RRMS), progressive multiple sclerosis (PMS).
There is still a lack of effective treatments, and on January 9, 2023, researchers from the IRCCS San Raffaele Institute of Science in Italy, among other institutions,
published a title in Nature Medicine, a top international medical journal Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
.
The study tried a new approach
to treating multiple sclerosis.
The research team collected donated embryonic stem cells from aborted fetuses at 10-12 weeks and injected them into the spine of multiple sclerosis patients, and successfully reduced the patients' disease markers
.
This is also the first Phase I clinical trial
to evaluate the safety of neural stem cell/precursor cell (hfNPC) transplantation of the human fetal central nervous system in patients with progressive MS.
Neural stem cells/precursor cells (NPCs) are mitotically active, self-renewing pluripotent cells capable of differentiating into mature brain cells, Reduces myelination and astrocytes and axon loss, exerts nutritional support and anti-inflammatory functions
.
NPCs derived from the central nervous system of the human fetus (hfNPCs), due to their ability to replicate under standardized and quality control conditions, can generate cell lines that can be used for nerve transplantation therapy, and their therapeutic properties have been demonstrated
in non-human primate experiments.
The clinical trial included four injections of embryonic stem cells
into 12 patients with multiple sclerosis.
Before the injection, all patients had severe symptoms and were already bedridden
.
In addition, each patient underwent a lumbar puncture in which spinal fluid was extracted from the spinal cord to measure multiple sclerosis markers – neuroprotective and anti-inflammatory molecular levels
.
Each patient also underwent an MRI scan to measure the volume of gray matter in the brain, as people with multiple sclerosis gradually lose brain mass
.
Three months later, each patient had another lumbar puncture, and the team found an increase
in neuroprotective and anti-inflammatory molecules in their spinal fluid.
Each patient also underwent an MRI scan two years after the embryonic stem cell injection, and those who injected the most embryonic stem cells had the least loss of gray matter in their brains.
Based on the current results, the research team said, it is too early
to determine whether symptoms have lessened or disease progression has slowed in these multiple sclerosis patients.
The research team will also continue to monitor these patients in the coming years to further see if embryonic stem cell therapy can alleviate symptoms and disease progression
in patients with multiple sclerosis.
Link to paper: style="font-size: 12px;color: rgb(136, 136, 136);" _mstmutation="1" _istranslated="1">
Open reprint, welcome to forward to Moments and WeChat groups
EditorWang Multifish
TypesettingShui Chengwen
Multiple Sclerosis (MS) is a neurodegenerative disease, Because the immune system mistakenly attacks and destroys the myelin sheath, involving the optic nerve, spinal cord, brainstem, periventricular white matter and other parts, resulting in clinical symptoms such as abnormal vision, limb movement disorder and ataxia, patients will gradually lose sensation and function
in the limbs and other parts of the body.
Although a variety of treatments for multiple sclerosis have been developed, there is no cure, and these therapies mainly target relapsing-remitting multiple sclerosis (RRMS), progressive multiple sclerosis (PMS).
There is still a lack of effective treatments, and on January 9, 2023, researchers from the IRCCS San Raffaele Institute of Science in Italy, among other institutions,
published a title in Nature Medicine, a top international medical journal Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
.
The study tried a new approach
to treating multiple sclerosis.
The research team collected donated embryonic stem cells from aborted fetuses at 10-12 weeks and injected them into the spine of multiple sclerosis patients, and successfully reduced the patients' disease markers
.
This is also the first Phase I clinical trial
to evaluate the safety of neural stem cell/precursor cell (hfNPC) transplantation of the human fetal central nervous system in patients with progressive MS.
Neural stem cells/precursor cells (NPCs) are mitotically active, self-renewing pluripotent cells capable of differentiating into mature brain cells, Reduces myelination and astrocytes and axon loss, exerts nutritional support and anti-inflammatory functions
.
NPCs derived from the central nervous system of the human fetus (hfNPCs), due to their ability to replicate under standardized and quality control conditions, can generate cell lines that can be used for nerve transplantation therapy, and their therapeutic properties have been demonstrated
in non-human primate experiments.
The clinical trial included four injections of embryonic stem cells
into 12 patients with multiple sclerosis.
Before the injection, all patients had severe symptoms and were already bedridden
.
In addition, each patient underwent a lumbar puncture in which spinal fluid was extracted from the spinal cord to measure multiple sclerosis markers – neuroprotective and anti-inflammatory molecular levels
.
Each patient also underwent an MRI scan to measure the volume of gray matter in the brain, as people with multiple sclerosis gradually lose brain mass
.
Three months later, each patient had another lumbar puncture, and the team found an increase
in neuroprotective and anti-inflammatory molecules in their spinal fluid.
Each patient also underwent an MRI scan two years after the embryonic stem cell injection, and those who injected the most embryonic stem cells had the least loss of gray matter in their brains.
Based on the current results, the research team said, it is too early
to determine whether symptoms have lessened or disease progression has slowed in these multiple sclerosis patients.
The research team will also continue to monitor these patients in the coming years to further see if embryonic stem cell therapy can alleviate symptoms and disease progression
in patients with multiple sclerosis.
Link to paper: style="font-size: 12px;color: rgb(136, 136, 136);" _mstmutation="1" _istranslated="1">
Open reprint, welcome to forward to Moments and WeChat groups
